Copyright
©The Author(s) 2022.
World J Clin Oncol. Apr 24, 2022; 13(4): 237-266
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.237
Published online Apr 24, 2022. doi: 10.5306/wjco.v13.i4.237
Table 2 Recommended stereotactic body radiation therapy dose in early-stage disease
| Localization | Dose | Ref. | Evidence level |
| Central tumour | 50/5 fx-60/5 fx | Bezjak et al[43], 2019 | II, B |
| 60 Gy/8 fx | Haasbeek et al[46], 2011 | ||
| Chest wall | 48 Gy/4 fx | Guckenberger et al[47], 2017 | II, B |
| 60 Gy/5 fx | Nagata et al[48], 2015 | ||
| 45 Gy/3 fx | Nyman et al[49], 2006 | ||
| Safe zone | 30 Gy/1 fx | Singh et al[50], 2019 | II, B |
| 34 Gy/1 fx | Videtic et al[31], 2019 | ||
| 54 Gy/3 fx | Timmerman et al[36], 2018 |
- Citation: Rodríguez De Dios N, Navarro-Martin A, Cigarral C, Chicas-Sett R, García R, Garcia V, Gonzalez JA, Gonzalo S, Murcia-Mejía M, Robaina R, Sotoca A, Vallejo C, Valtueña G, Couñago F. GOECP/SEOR radiotheraphy guidelines for non-small-cell lung cancer. World J Clin Oncol 2022; 13(4): 237-266
- URL: https://www.wjgnet.com/2218-4333/full/v13/i4/237.htm
- DOI: https://dx.doi.org/10.5306/wjco.v13.i4.237